These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 17013997)

  • 1. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
    Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
    Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
    Kakkassery V; Mergler S; Pleyer U
    Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?
    Roux CH; Brocq O; Leccia N; Giacchero D; Breuil V; Albert C; Lacour J; Perrin C; Euller-Ziegler L
    J Rheumatol; 2007 Feb; 34(2):434-7. PubMed ID: 17295430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor necrosis factor-alpha-induced psoriasis.
    Sari I; Akar S; Birlik M; Sis B; Onen F; Akkoc N
    J Rheumatol; 2006 Jul; 33(7):1411-4. PubMed ID: 16821276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
    Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
    Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies.
    Laga AC; Vleugels RA; Qureshi AA; Velazquez EF
    Am J Dermatopathol; 2010 Aug; 32(6):568-73. PubMed ID: 20520526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.
    Grinblat B; Scheinberg M
    Semin Arthritis Rheum; 2008 Feb; 37(4):251-5. PubMed ID: 17640718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    Ang HT; Helfgott S
    J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasiform and pustular eruption induced by infliximab.
    Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
    J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P; Cotena C; Tessari G; Girolomoni G
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.
    Brown SL; Greene MH; Gershon SK; Edwards ET; Braun MM
    Arthritis Rheum; 2002 Dec; 46(12):3151-8. PubMed ID: 12483718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
    Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
    J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.
    Ko JM; Gottlieb AB; Kerbleski JF
    J Dermatolog Treat; 2009; 20(2):100-8. PubMed ID: 18923992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.